Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 36,100 shares of the Company’s common stock at an exercise price per share of $16.09, which was the closing price on June 10, 2024, and restricted stock units to acquire a total of 18,050 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers
Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Arcus Biosciences Announces New Employment Inducement Grants
Merck stops testing combo drug for skin cancer as more patients discontinue
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update
Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024